A Snapshot Adaptive Optics and Hyperspectral Autofluorescence Fundus Camera for Age-Related Macular Degeneration (AMD)
Age: 18 - 95 years
Healthy Subjects: Yes
Recruitment Status: Recruiting
The purpose of this study is to learn more about age-related macular degeneration (AMD) by using a new investigational technology, AO-(adaptive optics) OCT (optical coherence tomography) with hyperspectral autofluorescence (AF). While currently there is no cure for AMD, with early diagnosis, vision loss can be slowed. AMD is a disease of the retinal pigment epithelium (a very thin cell layer found directly beneath the photoreceptor cells, which brings nutrients and oxygen to the photoreceptor cells), and the appearance of drusen (protein/lipid deposits or lesions) in the RPE is the earliest sign of AMD to be clinically detected. A clinical retinal imaging system that could detect the earliest signs of drusen in the eye could provide an early warning for individuals at risk for AMD, as well as enable the development and monitoring of new therapies. The technology being developed for this project, a snapshot ultra-high-resolution optical coherence tomographer autofluorescence system (AO-OCT/AF), will be the first imaging modality that can provide both structural and molecular information about the retina in vivo and in 3D.
- Subjects should have an intraocular lens implant
- Subjects should have no eye disease
- Subjects should be in overall good health
- Subjects must be aged 60 and over and pseudophakic, with clear posterior capsule and dilation to 6mm.
- Subjects will have age-related macular degeneration.
- Subjects must be diagnosed early/intermediate AMD in at least one eye (the study eye) with soft drusen or reticular pseudodrusen in the macula.
- Retinopathy other than AMD.
- Inability to give informed consent
- Bilateral advanced AMD
- Allergy to dilation eye drops
- Age Related macular Degeneration (AMD)